AT 406

Drug Profile

AT 406

Alternative Names: AT-406; Debio-1143; SMAC mimetic - Debio-1143

Latest Information Update: 19 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ascenta Therapeutics
  • Developer 3SBio; Ascenta Therapeutics; Debiopharm Group; The Leukemia & Lymphoma Society
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Inhibitor of apoptosis protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Head and neck cancer; Ovarian cancer
  • Phase I Breast cancer; Non-small cell lung cancer; Solid tumours
  • No development reported Acute myeloid leukaemia; Lymphoma
  • Discontinued Leukaemia

Most Recent Events

  • 15 Jun 2017 Debiopharm completes enrolment in a phase I/II trial in Head and neck cancer (Combination therapy, First line therapy) in France and Switzerland
  • 24 Oct 2016 Debiopharm, Merck and Pfizer plan a phase I/Ib trial for Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease)
  • 20 Oct 2016 Debiopharm, Merck and Pfizer enter into a collaboration agreement for a phase I/Ib trial of AT 406 for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top